Back to all news

Trading News

Trading, exchanges and market analysis

Latest News

Real-time updates about Trading

Loading more news...

Article Details

Read Original
Tokenist

Why Did Biohaven Stock Collapse in Premarket Today? FDA Rejects Its Lead Drug Vyglxia

Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as data showed slower disease progression.The post Why Did Biohaven Stock Collapse in Premarket Today? FDA Rejects Its Lead Drug Vyglxia appeared first on Tokenist.

0 |
0
🐂
🐻

Categories